Social Behavior – Page 2

Recent Moves in Biotech Leadership

2 weeks ago talkbio0Tagged biotech, eli lilly, Leadership, Moderna, Peter Marks

Biotech; Leadership; Moderna; Eli Lilly; Peter Marks

The 5 Most Powerful Women in Biopharma: 2025 News & Key Figures

3 weeks ago talkbio0Tagged Belén, Biopharma, CEO, Garijo, Leadership, Reshma Kewalramani, Sarah Boyce, Woman, Women, Yvonne Greenstreet

powerful women; biopharma; female CEO; Reshma Kewalramani; Yvonne Greenstreet; Sarah Boyce; Emma Walmsley; Belén Garijo; leadership

Novartis Receives FDA Approval for Rhapsido: First Oral BTK Inhibitor for Chronic Hives

4 weeks ago talkbio0Tagged Approved, Bruton 's tyrosine kinase inhibitor, BTKi, chronic hives, Chronic Spontaneous Urticaria, competition, Immunology, Novartis, Oral Therapy, remibrutinib, Rhapsido, United States Food and Drug Administration

Novartis; Rhapsido; FDA approval; Bruton’s tyrosine kinase inhibitor (BTKi); remibrutinib; chronic spontaneous urticaria (CSU); chronic hives; immunology; oral therapy; competition

Novartis Inks Second Molecular Glue Deal With Monte Rosa Worth Up to $5.7 Billion

1 month ago talkbio0Tagged Autoimmune Diseases, Collaboration, Drug Discovery, Immunology, molecular glue degraders, Monte Rosa Therapeutics, Novartis, QuEEN, royalties, upfront payment

Novartis; Monte Rosa Therapeutics; molecular glue degraders; $5.7 billion deal; drug discovery; immunology; QuEEN platform; autoimmune diseases; upfront payment; royalties; collaboration

Novartis Expands Degrader-Focused Collaboration with Monte Rosa Through Major Molecular Glue Deal

1 month ago talkbio0Tagged AI/ML-enabled product, Collaboration, Drug Discovery, engine, immune-mediated diseases, milestone payments, molecular glue degraders, Monte Rosa Therapeutics, MRT-6160, Novartis, VAV1 protein

Novartis; Monte Rosa Therapeutics; molecular glue degraders; MRT-6160; VAV1 protein; immune-mediated diseases; drug discovery; collaboration; milestone payments; AI/ML-enabled product engine

Eli Lilly Loses Appeal to Overturn $183.7 Million Medicaid Rebate Judgment

1 month ago talkbio0Tagged appeal, Circuit, court, drug price, eli lilly, False Claims Act, Fraud, judgment, Medicaid, Positive

Eli Lilly; Medicaid; rebate; court ruling; False Claims Act; drug pricing; whistleblower; 7th Circuit Court of Appeals; fraud; $183.7 million judgment

Novo Nordisk to Cut 9,000 Jobs Globally as New CEO Targets $1.3B Savings by 2026

2 months ago talkbio0Tagged CEO, competition, Doustdar, eli lilly, Financial cost, Financial savings, layoffs, Nordisk, Ozempic, profit guidance, restructuring, Wegovy, Weight-Loss Agents

Novo Nordisk; layoffs; 9000 jobs; cost savings; CEO Doustdar; restructuring; weight-loss drugs; Wegovy; Ozempic; competition; Eli Lilly; profit guidance

RFK Jr. Blasts Pharma Industry and Spreads mRNA Vaccine Misinformation During Heated Senate Hearing

2 months ago talkbio0Tagged Centers for Disease Control and Prevention (U.S.), COVID19 (disease), Leadership, mRNA misinformation, Pharma Industry, Policy, public health medicine (field), RFK Jr., Senate hearing, Vaccines

RFK Jr.; Senate hearing; pharma industry; mRNA misinformation; COVID-19 vaccines; public health; vaccine policy; CDC leadership

ESC25: GE HealthCare Showcases AI Cardiology Innovations for Earlier and More Accurate Diagnoses

2 months ago talkbio0Tagged Artificial Intelligence, authorization, Cardiac imaging, Cardiology discipline, CardIQ, Diagnostic Accuracy, Electrophysiology (science), ESC25, GE HealthCare, Molecular Imaging, Revolution Vibe CT, United States Food and Drug Administration, ViewPoint EchoPilot, workflow automation

GE HealthCare; ESC25; AI cardiology; diagnostic accuracy; ViewPoint EchoPilot; CardIQ Suite; Revolution Vibe CT; molecular imaging; workflow automation; electrophysiology; cardiac imaging; FDA authorization

Indivior Initiates Cost-Cutting Plan with Job Cuts and Real-Estate Review

2 months ago talkbio0Tagged Advice, competition, cost-cutting, Generic Drugs, Indivior, Opvee divestiture, profit guidance, real-estate, restructuring, Sales - occupational activity

Indivior; job cuts; real-estate; cost-cutting; restructuring; sales guidance; profit guidance; Opvee divestiture; competition; generic drugs